论文部分内容阅读
慢性淋巴细胞白血病(CLL)是由于一种淋巴细胞克隆性增殖,逐步积累而浸润骨髓、血液、淋巴结和其它器官,最终导致造血功能衰竭的一种恶性疾病。CLL通常发生干60岁以上的老年人,男性多于女性。无症状患者的预期寿命与一般人群差异不大,但应定期随访。瘤可宁是标准治疗药物,能延缓有症状患者的进展;瘤可宁治疗无效时常使用氟达拉滨单药或联合其它制剂进行治疗;单克隆抗体也是治疗CLL的一种较有希望的药物;此外,同种移植能使部分CLL患者获得治愈。
Chronic lymphocytic leukemia (CLL) is a malignant disease that eventually leads to hematopoietic failure due to a clonal proliferation of lymphocytes that gradually accumulates and infiltrates the bone marrow, blood, lymph nodes and other organs. CLL usually occurs in people over 60 years of age, more men than women. The life expectancy of asymptomatic patients and the general population is not different, but should be followed up regularly. Oncolytic is a standard treatment that delays the progress of patients with symptomatic disease. Chemotherapy is often treated with fludarabine alone or in combination with other agents. Monoclonal antibodies are also a promising drug for the treatment of CLL ; In addition, allografts can make some patients with CLL cured.